Press Releases Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-07-11 EDT			5-day change	1st Jan Change
4,378.00 ^JPY	+0.97%		-1.40%	+4.71%

07-08	Takeda Completes Treasury Share Disposal Under Overseas Employee Incentive Plan	MT
07-07	US FDA approves KalVista's oral swelling disorder drug, shares rise	RE

Press Releases

Takeda Pharmaceutical : Filing of Corporate Governance Report to the Tokyo Stock Exchange	07-09	PU
Takeda Pharmaceutical : Completes Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees	07-08	PU
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1	06-30	BU
Takeda Pharmaceutical : Integrated Report (takeda 2025 annual integrated report en)	06-30	PU
Takeda Pharmaceutical : Announces Pricing of Unsecured U.S. Dollar-Denominated Senior Guaranteed Notes	06-26	PU
Takeda Announces New Assignments of Directors	06-25	BU
Takeda Pharmaceutical : Notice of Resolutions at the 149th Annual General Meeting of Shareholders	06-25	PU
Takeda Pharmaceutical : Notice Concerning Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan	06-10	PU
Takeda Pharmaceutical : Sets Terms and Conditions for its Yen Denominated Unsecured Senior Bonds	06-05	PU
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 149th Annual General Meeting of Shareholders	06-05	PU
Takeda - European Commission Approves ADCETRIS for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD	06-04	AQ
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD	06-03	BU
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera	06-01	BU
Takeda Pharmaceutical : Notice of Convocation of the 149th Annual General Meeting of Shareholders	05-28	PU
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award	05-27	BU
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1	05-14	BU
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth and Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress	05-09	AQ
Takeda Pharmaceutical : PresentationPresentationDownload Presentation (qr2024 q4 p01 en v1)	05-09	PU
Takeda Pharmaceutical : Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2025	05-08	PU
Takeda Pharmaceutical : Earnings Report（Kessan Tanshin）Earnings Report（Kessan Tanshin）Download Earnings Report（Kessan Tanshin） (qr2024 q4 er en)	05-08	PU
Takeda Pharmaceutical : PresentationPresentationDownload Presentation (qr2024 q4 p01 en)	05-08	PU
Takeda Pharmaceutical : Quarterly Financial ReportQuarterly Financial ReportDownload Quarterly Financial Report (qr2024 q4 qfr en)	05-08	PU
Takeda Pharmaceutical : Quarterly Highlights InfographicQuarterly Highlights InfographicDownload Quarterly Highlights Infographic (FY24Q4 EN Takeda Infographic)	05-08	PU
Takeda Pharmaceutical : Clinical Trials Summary (Clinical Trial Summary May 2025)	05-08	PU
Takeda Pharmaceutical : Epidemiology Data (FY24 Q4 Epidemiology data)	05-08	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Takeda CEO Weber on Drug Pipeline, Geopolitical Risks

January 13, 2025 at 03:45 pm